Did the authors limit the types of persons with Parkinsons disease who were allowed to enroll in the trial
The problem with heart disease is that it rarely develops overnight
Inflammation 40 , 861870 (2017)
Christopher Hanley is an associate professor and chair of clinical pharmacology at Manhattanville Universitys School of Nursing and Health Sciences in Harrison, New York
Depending on the patient, monitoring may include: Weight trends Waist circumference Blood pressure Glucose and A1C Lipids Liver markers Kidney markers Thyroid markers when appropriate Nutrient markers when indicated Hormone considerations when relevant Adjust the Plan as the Body Changes A patients needs at the start of treatment may not be the same after losing 20, 40, or 60 pounds
Any successful treatment, whether it involves GLP-1 medications, surgery, nutritional changes, or a combination of all three, needs to address your bodys internal setpoint rather than just fighting against it